ArticleJournal of cardiothoracic surgery2026
Predictors of target lesion restenosis after endovascular therapy for lower-extremity atherosclerotic peripheral artery disease: a real-world single center cohort.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLower-extremity peripheral artery disease often requires endovascular therapy. Target-lesion restenosis (TLRS) remains frequent, but current risk stratification is limited.
methodsWe retrospectively analyzed 1,005 lesions from 917 patients undergoing endovascular therapy for lower-extremity atherosclerotic disease at a single center (2019-2024) with scheduled surveillance (approximately 6, 12, and 24 months) and administrative censoring at 36 months. The primary endpoint was time to first TLRS ≥ 50%, adjudicated by duplex ultrasound (peak systolic velocity ratio criteria) or CTA/DSA when available. Lesion‑level Fine-Gray competing‑risk models (death as a competing event) with patient‑level clustering were used. A prespecified Core model (clinical, anatomic, procedural/device covariates and C‑reactive protein) was compared with an Extended model additionally including the Atherogenic Index of Plasma (AIP) and log‑transformed Systemic Immune-Inflammation Index (SII). Models were internally validated by 1,000 bootstrap resamples and assessed at the 24‑month horizon using the C‑index, calibration, Brier score, integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision‑curve analysis.
resultsAmong 917 patients (1,005 lesions), mean age was 75.2 ± 11.7 years and 68.6% were male. At 24 months, cumulative incidences were 31.4% for TLRS, 14.9% for clinically driven target‑lesion revascularization, and 12.3% for death. In multivariable analyses, GLASS stage III, lesion length ≥ 150 mm, residual stenosis > 20%, chronic kidney disease, and Rutherford class 4-6 predicted higher TLRS risk, whereas good distal runoff was protective. In the Extended model, AIP and SII remained independent predictors and improved the optimism‑corrected 24‑month C‑index from 0.68 to 0.73 (Δ0.05, p = 0.002), reduced the Brier score (0.19 to 0.17), yielded positive IDI and NRI, and preserved good calibration. Exploratory analyses suggested lower TLRS risk with cilostazol and low‑dose rivaroxaban plus aspirin.
conclusionsAIP and SII improved lesion-level prediction of TLRS beyond conventional covariates. The Extended model may support risk-tiered surveillance after endovascular therapy; external validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.